^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Prostate Cancer

    Related cancers:
    16h
    A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) (clinicaltrials.gov)
    P2, N=138, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Nov 2028 --> May 2028 | Trial primary completion date: Jan 2028 --> Jul 2027
    Trial completion date • Trial primary completion date
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • luxdegalutamide (ARV-766)
    17h
    Robotic Telesurgery in Urology (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Case Comprehensive Cancer Center
    New trial
    17h
    EvoPAR-PR02: A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation (clinicaltrials.gov)
    P3, N=700, Recruiting, AstraZeneca
    Trial initiation date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    abiraterone acetate • prednisone • saruparib (AZD5305)
    18h
    Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov)
    P1/2, N=52, Recruiting, Weill Medical College of Cornell University | Active, not recruiting --> Recruiting | N=37 --> 52
    Enrollment open • Enrollment change
    |
    CELLSEARCH®
    |
    Keytruda (pembrolizumab) • Xtandi (enzalutamide) • Ac-225 rosopatamab tetraxetan (CONV01-α)
    19h
    A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Tazverik (tazemetostat) • AiRuiEn (rezvilutamide) • HRS-5041
    20h
    Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations (clinicaltrials.gov)
    P4, N=43, Active, not recruiting, AstraZeneca | Completed --> Active, not recruiting | Trial completion date: Jul 2025 --> Dec 2026
    Enrollment closed • Trial completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset)
    |
    BRCA2 mutation • BRCA1 mutation
    |
    Lynparza (olaparib) • Xtandi (enzalutamide) • abiraterone acetate • prednisone
    21h
    The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer (clinicaltrials.gov)
    P1, N=13, Not yet recruiting, FindCure Biosciences (ZhongShan) Co., Ltd.
    New P1 trial
    22h
    EZHiSWITCH: Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors. (clinicaltrials.gov)
    P2, N=900, Recruiting, Gustave Roussy, Cancer Campus, Grand Paris
    Trial initiation date
    |
    ARID1A (AT-rich interaction domain 1A) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • PBRM1 (Polybromo 1) • BAP1 (BRCA1 Associated Protein 1) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • SMARCA2 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A, Member 2)
    |
    Ezharmia (valemetostat)
    22h
    LaserSAFE: A Study to Evaluate the Performance of Confocal Microscopy to Detect Positive Margins During Radical Prostatectomy (clinicaltrials.gov)
    P=N/A, N=693, Not yet recruiting, University College, London
    New trial
    23h
    A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Regeneron Pharmaceuticals
    New P1 trial
    |
    BPX-601
    1d
    BUS-006/RAP: A phase II, double-blind, randomised, placebo-controlled trial to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories versus placebo for amelioration of acute radiation proctitis symptoms (2024-519359-27-00)
    P1/2, N=320, Not yet recruiting, Dr. Falk Pharma GmbH | N=160 --> 320
    Enrollment change
    1d
    EMUPRO: Comparison of Radical Prostatectomy Performed by Robot-assisted Laparoscopy or Conventional Laparoscopy or by Laparotomy (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, Elsan | Trial primary completion date: Apr 2025 --> Jul 2025
    Trial primary completion date